$83.5 million NIH grant to Pitt establishes Clinical and Translational Research Institute

October 03, 2006

PITTSBURGH, Oct. 3 - The University of Pittsburgh is among the first institutions selected by the National Institutes of Health (NIH) to receive a Clinical and Translational Science Award, joining 11 other academic health centers in a new consortium that aims to transform how clinical and translational research is conducted so that promising treatments can be more readily available to patients.

The award means that Pitt will receive a total of $83.5 million over five years to establish the Clinical and Translational Science Institute (CTSI), which will foster the development of clinical and translational research as a distinct field and promote the application of biomedical research advances into clinical practice. The award is one of the largest NIH grants the University has ever received.

The CTSI will be led by Steven E. Reis, M.D., associate vice chancellor for clinical research, Health Sciences, and will include Pitt's schools of Medicine, Nursing, Pharmacy, Dental Medicine, Health and Rehabilitation Sciences and the Graduate School of Public Health; the University of Pittsburgh Medical Center; Carnegie Mellon University; RAND Corporation; the Intel Research Pittsburgh lab; and as a community partner, the Urban League of Pittsburgh.

"The development of this consortium represents the first systematic change in our approach to clinical research in 50 years," said NIH Director Elias A. Zerhouni, M.D. "Working together, these sites will serve as discovery engines that will improve medical care by applying new scientific advances to real world practice. We expect to see new approaches reach underserved populations, local community organizations and health care providers to ensure that medical advances are reaching the people who need them."

Institutions competing for the awards were required to "build academic homes for clinical and translational science" through an infrastructure that would consolidate their existing resources with new initiatives; foster new research, training and community-focused programs that ensure patients, especially minority and the underserved, have greater access to clinical trials; and promote collaborations among departments, schools, other local institutions and industry to enable the adoption of new medical therapies into clinical practice. In response, Pitt proposed establishing an institute that, in its broadest sense, would catalyze changes in the scientific enterprise.

"The University of Pittsburgh is committed to this endeavor, and we fully understand that to be successful, we must lead and facilitate a transformation that will result in fundamental changes within our own institution, in how scientists are trained and perform research, and in the practice of medicine in western Pennsylvania.," said Dr. Reis. "We have to change existing paradigms and break down barriers; otherwise, we will have failed to achieve the ultimate goal of the NIH-led consortium, which is to ensure that advances in biomedical research quickly find their way into clinical practice."

Within the first few years of funding, the CTSI will begin training a new cadre of clinical scientists, starting with programs at the high school level; address minority and health disparities in the region through new initiatives, including the establishment of the CTSI Braddock Minority Health Clinical and Translational Research Center at UPMC Braddock; and improve access to and increase participation in clinical trials through a novel institutional research subject registry to be embedded in UPMC's electronic health record system and implemented at UPMC's 350 outpatient practice locations and 19 hospitals. The registry will enable patients who have given prior consent to receive comprehensive health information and educational materials and to be offered opportunities to improve their health through participation in clinical research.

The CTSI also will enable the launch of novel methodologies. One application will evaluate breast lesions depicted on mammograms and pathology slides based on an open-source software system jointly created by Intel Research and Carnegie Mellon University. Called Diamond, it allows rapid scanning and searching of large volumes of images. Funding to develop other innovative clinical and translational methodologies will be available to investigators through the CTSI.

"While we have a rich history of translating innovative biomedical discoveries, beginning with the development of the polio vaccine, one of our most critical strengths we bring to a new institute focused on translational science is rooted in a culture that values and encourages collaboration. As a university and a community, we have greatly benefited from our decades-long relationship with colleagues at Carnegie Mellon University, and through our extremely close affiliation with UPMC, we support and share a common commitment to excellence in research, education and clinical care," said Arthur S. Levine, M.D., senior vice chancellor for the health sciences at the University of Pittsburgh and dean of the medical school.

The CTSI will consist of four main areas: education and career development, which will be headed by Wishwa Kapoor, M.D., M.P.H.; translational research, headed by Robert A. Branch, M.D.; clinical research, which Dr. Reis will direct; and clinical and translational bioinformatics, directed by Michael Becich, M.D., Ph.D. Innovative interdisciplinary research initiatives will be developed through 10 CTSI resource cores and translated to clinical practice through a community partnership program that involves UPMC's extensive clinical networks and the Urban League of Pittsburgh, which likely will house a CTSI satellite office and clinic. The community partnership program will be led by Jacqueline Dunbar-Jacob, Ph.D., R.N., F.A.A.N., dean of the School of Nursing.
The Clinical and Translational Science Award initiative was established by the NIH as a commitment to re-engineer the clinical research enterprise, one of the key objectives of the NIH Roadmap for Medical Research. When fully implemented in 2012, the initiative will include 60 academic medical centers.

The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences and the Graduate School of Public Health. The schools serve as the academic partner of the University of Pittsburgh Medical Center. Together, their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease, and participate in the delivery of outstanding patient care. For fiscal year 2005, Pitt and its institutional affiliates ranked 7th nationally among more than 3,000 entities whose research is supported by grants from the National Institutes of Health.

University of Pittsburgh Medical Center

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.